---
title: "Extended PRS Incorporating Multilocus Burden and Epistasis Improves Risk Prediction for Type 2 Dia"
id: "medrxiv-8-additive-multilocus-burden-and-epistatic-interactions-improves-genetic-risk"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-8-additive-multilocus-burden-and-epistatic-interactions-improves-genetic-risk"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.12.26360291v1?rss=1"
published_at: "2026-08-14T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Extended PRS Incorporating Multilocus Burden and Epistasis Improves Risk Prediction for Type 2 Dia
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-8-additive-multilocus-burden-and-epistatic-interactions-improves-genetic-risk
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.12.26360291v1?rss=1)
- **Published At:** 2026-08-14T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The authors developed an extended polygenic risk score framework (**ePRS**) that adds non-additive, locus-by-locus effects to standard additive **polygenic risk scores**. - Non-additive components modelled include cumulative multilocus burden (G+G), statistical **epistasis** (GxG), and gene–environment interactions using cardiometabolic variables from electronic health records. - Analysis used data from 235,000 UK Biobank participants and identified five complementary ePRS models that flagged largely non-overlapping high-risk individuals, indicating multiple interaction-driven components contribute to individual risk predictions. - A composite score combining these components improved case detection beyond clinical predictors and identified risk in people with clinically normal ranges for conventional measures. - The approach generalized to celiac disease, showing similar complementarity across models, suggesting potential broader applicability. - Code is available on GitHub (https://github.com/keri/prsInteractive) and the work is a preprint pending peer review; prospective validation is required before clinical use. - Ethical approval was through the North West Multi-centre Research Ethics Committee (REC reference 21/NW/0157) and analyses used UK Biobank resources under project 86965. - The report emphasizes that additive single-locus PRS and LD tagging do not capture all heritable risk and that including multilocus and environment interaction terms may capture additional broad-sense heritability.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=sI57QJeJ.9eWoZjp5a0IUXprIR8SyOgmeYaeZ7D7iWY-1786715109.2937672-1.2.1.1-PjskbOLUkODbf6vkXXV03cb3L_GpoVr1rB43cPQSj8dJiP7EqrZSKKgp0xN7O765) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.12.26360291v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Additive Multilocus Burden and Epistatic Interactions Improves Genetic Risk Predictions for Complex Diseases [ View ORCID Profile](http://orcid.org/0009-0004-2859-0708)Keri Multerer, Paul Atkinson, Lisa Woods, [ View ORCID Profile](http://orcid.org/0000-0001-9759-157X)Yosuke Tanigawa, [ View ORCID Profile](http://orcid.org/0000-0001-7113-9630)Manolis Kellis, [ View ORCID Profile](http://orcid.org/0000-0003-3033-395X)Andrew Munkacsi doi: https://doi.org/10.64898/2026.08.12.26360291 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Keri Multerer 1 Victoria University of Wellington; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Keri%2BMulterer%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Multerer%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKeri%2BMulterer%2B) * [ORCID record for Keri Multerer](http://orcid.org/0009-0004-2859-0708 "Open in new tab") * For correspondence: keri.multerer@vuw.ac.nz Paul Atkinson 1 Victoria University of Wellington; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Paul%2BAtkinson%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Atkinson%20P&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APaul%2BAtkinson%2B) Lisa Woods 1 Victoria University of Wellington; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Lisa%2BWoods%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Woods%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALisa%2BWoods%2B) Yosuke Tanigawa 2 University of California, Los Angeles; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Yosuke%2BTanigawa%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Tanigawa%20Y&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AYosuke%2BTanigawa%2B) * [ORCID record for Yosuke Tanigawa](http://orcid.org/0000-0001-9759-157X "Open in new tab") Manolis Kellis 3 Massachusetts Institute of Technology * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Manolis%2BKellis%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kellis%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AManolis%2BKellis%2B) * [ORCID record for Manolis Kellis](http://orcid.org/0000-0001-7113-9630 "Open in new tab") Andrew Munkacsi 1 Victoria University of Wellington; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Andrew%2BMunkacsi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Munkacsi%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAndrew%2BMunkacsi%2B) * [ORCID record for Andrew Munkacsi](http://orcid.org/0000-0003-3033-395X "Open in new tab") * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.12.26360291v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1278353/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.12.26360291v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1278353/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.12.26360291v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1278353/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.08.12.26360291v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1278353/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.12.26360291v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1278353/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.12.26360291v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1278353/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Polygenic risk scores (PRS) assume additive SNP effects, yet genetic risk also arises from interactions between loci and environmental factors that contribute to broad-sense heritability. We developed an extended PRS (ePRS) framework for type 2 diabetes (T2D) that incorporates locus-by-locus non-additive effects beyond those captured by additive single-locus PRS or linkage disequilibrium (LD) tagging. These were modelled as cumulative burden (G+G; summed allele counts), statistical epistasis (GxG; allele count products), and gene-environment effects derived from cardiometabolic variables in electronic health records. Across 235,000 UK Biobank participants, five complementary ePRS models captured largely non-overlapping high-risk individuals, suggesting that a key to individual risk predictions comprise the inclusion of multiple interaction-driven biological components rather than a single signal. A composite score improved case detection beyond clinical predictors, including individuals within clinically normal ranges. These findings were generalized to celiac disease, with similar complementarity across models, with potential for clinical use pending prospective validation. ### Competing Interest Statement Y.T. holds a visiting Associate Professorship at Kyoto University and a visiting researcher position at the University of Tokyo for collaboration; those affiliations have no role in study design, data collection, data analysis, the decision to publish, or the preparation of the manuscript. No other authors have competing interests to declare. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: North West Multi-centre Research Ethics Committee of the Health Research Authority gave ethical approval for this work (REC reference 21/NW/0157), granted to UK Biobank as a Research Tissue Bank. This research was conducted using the UK Biobank Resource under project 86965. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All data produced in the present work are contained in the manuscript. All code used in analysis can be found in the GitHub repository: https://github.com/keri/prsInteractive. ## Funder Information Declared SHEADI Faculty Strategic Research Grants, Victoria University of Wellington, 410125 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.12.26360291v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.13.26360376v1 "20+ years of mass drug administration against urogenital schistosomiasis on the Zanzibar islands: Is praziquantel still efficacious?")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.12.26360302v1 "Beyond Signal Detection: Sequential Target Trial Emulations to Confirm Previously Detected Adverse Drug Event Signals for Atorvastatin in Older Medicare Beneficiaries") Posted August 14, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.12.26360291v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/08/14/2026.08.12.26360291.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.12.26360291v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.08.12.26360291v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/08/14/2026.08.12.26360291.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Additive Multilocus Burden and Epistatic Interactions Improves Genetic Risk Predictions for Complex Diseases Keri Multerer, Paul Atkinson, Lisa Woods, Yosuke Tanigawa, Manolis Kellis, Andrew Munkacsi medRxiv 2026.08.12.26360291; doi: https://doi.org/10.64898/2026.08.12.26360291 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.12.26360291v1%26text%3DAdditive%2520Multilocus%2520Burden%2520and%2520Epistatic%2520Interactions%2520Improves%2520Genetic%2520Risk%2520Predictions%2520for%2520Complex%2520Diseases "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.12.26360291v1%26t%3DAdditive%2520Multilocus%2520Burden%2520and%2520Epistatic%2520Interactions%2520Improves%2520Genetic%2520Risk%2520Predictions%2520for%2520Complex%2520Diseases "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.12.26360291v1%26title%3DAdditive%2520Multilocus%2520Burden%2520and%2520Epistatic%2520Interactions%2520Improves%2520Genetic%2520Risk%2520Predictions%2520for%2520Complex%2520Diseases%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.12.26360291v1%26title%3DAdditive%2520Multilocus%2520Burden%2520and%2520Epistatic%2520Interactions%2520Improves%2520Genetic%2520Risk%2520Predictions%2520for%2520Complex%2520Diseases "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.12.26360291) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.12.26360291v1&count=horizontal&via=&text=Additive%20Multilocus%20Burden%20and%20Epistatic%20Interactions%20Improves%20Genetic%20Risk%20Predictions%20for%20Complex%20Diseases&counturl=www.medrxiv.org/content/10.64898/2026.08.12.26360291v1 "Tweet This") ## Subject Area * [Genetic and Genomic Medicine ](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (604) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (891) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (324) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4715) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (469) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (403) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (633) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1601) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15720) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1187) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6922) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (723) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1043) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (4909) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1416) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1715) * [Hematology](https://www.medrxiv.org/collection/hematology) (571) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1318) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16189) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1151) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (655) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (150) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (713) * [Neurology](https://www.medrxiv.org/collection/neurology) (7091) * [Nursing](https://www.medrxiv.org/collection/nursing) (358) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1064) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1214) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (990) * [Oncology](https://www.medrxiv.org/collection/oncology) (3536) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1023) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (384) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (437) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (460) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (136) * [Pathology](https://www.medrxiv.org/collection/pathology) (700) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1760) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (726) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (754) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5773) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9601) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2351) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1415) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1231) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (629) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (759) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (571) * [Surgery](https://www.medrxiv.org/collection/surgery) (754) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (106) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (300) * [Urology](https://www.medrxiv.org/collection/urology) (281) Evaluation/discussion of this paper x Comments 0TRiP 0Community 0Automated 0Blogs/Media 0Video 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions. The content of a comment is not endorsed by medRxiv. medRxiv is now using a new commenting interface powered by Hypothes.is. All comments previously submitted via the
## Related Clinical Research

- [Undiagnosed type 2 diabetes presenting as DKA with hypertriglyceridemia-induced acute pancreatitis](https://medichelpline.com/clinical-feed/cmaj-1-undiagnosed-type-2-diabetes-presenting-as-diabetic-ketoacidosis-with.md)
- [North West London Diabetes Cohort: multiethnic EHR resource for diabetes complications research](https://medichelpline.com/clinical-feed/bmj-open-2-large-scale-multiethnic-electronic-health-record-resource-for-diabetes.md)
- [Pharma Friday: FDA OKs Rasonque for Metastatic Pancreatic Cancer and Mounjaro CV Approval — Sept 4](https://medichelpline.com/clinical-feed/endocrine-news-0-pharma-friday-september-4-2026.md)
- [Yoga-Based Lifestyle Intervention to Improve Endothelial Function in Type 2 Diabetes: Protocol of](https://medichelpline.com/clinical-feed/bmj-open-17-effect-of-yoga-based-lifestyle-intervention-on-endothelial-function-and.md)
- [Semaglutide Associated With Lower Bone Fracture Risk in Type 2 Diabetes](https://medichelpline.com/clinical-feed/endocrine-news-0-video-semaglutide-linked-to-lower-bone-fracture-risk.md)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.